URECHOLINE Drug Patent Profile

Which patents cover Urecholine, and when can generic versions of Urecholine launch?

Urecholine is a drug marketed by Teva Branded Pharm and Odyssey Pharms and is included in five NDAs.

The generic ingredient in URECHOLINE is bethanechol chloride. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bethanechol chloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Urecholine

A generic version of URECHOLINE was approved as bethanechol chloride by UPSHER SMITH LABS on June 1^st, 2005.

Summary for URECHOLINE

US Patents:	0
Applicants:	2
NDAs:	5
Raw Ingredient (Bulk) Api Vendors:	84
Clinical Trials:	1
Patent Applications:	1,560
DailyMed Link:	URECHOLINE at DailyMed

Recent Clinical Trials for URECHOLINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Augusta University	Phase 1

See all URECHOLINE clinical trials

US Patents and Regulatory Information for URECHOLINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	URECHOLINE	bethanechol chloride	INJECTABLE;INJECTION	006536-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Teva Branded Pharm	URECHOLINE	bethanechol chloride	TABLET;ORAL	006536-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Odyssey Pharms	URECHOLINE	bethanechol chloride	TABLET;ORAL	088441-001	May 29, 1984		DISCN	Yes	No
Teva Branded Pharm	URECHOLINE	bethanechol chloride	TABLET;ORAL	006536-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Odyssey Pharms	URECHOLINE	bethanechol chloride	TABLET;ORAL	089095-001	Dec 19, 1985		DISCN	No	No

Urecholine Market Dynamics and Financial Trajectory: Bethanechol Chloride Patent, Generic, and Commercial Analysis

Last updated: August 12, 2026

Urecholine is the former brand name for bethanechol chloride, an oral cholinergic agonist used primarily for nonobstructive urinary retention and neurogenic bladder. Its commercial profile is defined by generic substitution, limited clinical demand, low pricing, and the absence of meaningful surviving brand exclusivity. No reliable public source reports standalone Urecholine revenue, and the product should be analyzed as a mature generic market rather than as an innovator pharmaceutical franchise.

What is Urecholine and how is bethanechol used?

Urecholine contains bethanechol chloride, a direct-acting parasympathomimetic that stimulates muscarinic receptors and increases bladder detrusor tone. The FDA-approved labeling identifies urinary retention caused by postoperative or postpartum conditions and neurogenic bladder dysfunction as the principal uses.[1]

Attribute	Urecholine / bethanechol chloride
Active ingredient	Bethanechol chloride
Drug class	Direct-acting cholinergic agonist
Primary dosage form	Immediate-release oral tablet
Historical strengths	5 mg, 10 mg, 25 mg, 50 mg
Main indications	Nonobstructive urinary retention; neurogenic bladder atony
Administration	Oral
FDA regulatory category	Small-molecule prescription drug
Current market structure	Generic-dominated
Biosimilar exposure	None
Standalone brand revenue disclosure	Not publicly reported

Bethanechol does not treat mechanical urinary obstruction. The label warns against use where obstruction exists because increased bladder contraction can raise pressure against the obstruction and worsen clinical risk.[1]

Clinical demand is concentrated in hospital discharge prescribing, urology, post-surgical care, rehabilitation, and selected neurogenic bladder cases. Use is constrained by adverse effects such as abdominal cramps, diarrhea, sweating, salivation, bronchospasm, hypotension, and bradycardia.[1]

When did Urecholine lose exclusivity?

Urecholine lost practical exclusivity decades ago. Bethanechol is an old small-molecule drug, and the original composition-of-matter patent period expired long before the modern generic market developed. No active patent estate is known to protect the bethanechol molecule or the historical Urecholine product.

The commercial protection timeline is best summarized as follows:

Exclusivity category	Urecholine status
Original molecule patent	Expired
Original product patents	Expired or commercially irrelevant
New chemical entity exclusivity	Not applicable under current framework
Pediatric exclusivity	No material current relevance identified
Orphan-drug exclusivity	Not applicable
Data exclusivity	Expired
Brand exclusivity	Expired
Generic competition	Established
Current patent-based launch barrier	None identified

The precise original Urecholine approval and patent chronology is difficult to reconstruct from modern public databases because the product predates the current electronic FDA approval-record system. That historical limitation does not change the market conclusion: Urecholine is a long-off-patent product with generic availability.

What patents protect Urecholine today?

No commercially meaningful active U.S. patent is known to protect Urecholine or bethanechol chloride as an active ingredient. The relevant intellectual-property position is weak.

Composition-of-matter protection

Bethanechol is an established active pharmaceutical ingredient. Any original compound patent expired many years ago. A new patent covering the same basic molecule would generally face novelty and obviousness barriers because bethanechol is prior art.

Formulation patents

The historical Urecholine product was an immediate-release tablet. No widely recognized active formulation patent currently creates a barrier to generic bethanechol tablets. Tablet excipients, manufacturing parameters, and packaging may be protected in isolated cases, but those rights would not prevent competitors from producing a bioequivalent product using different formulation technologies.

Method-of-use patents

No material active method-of-use patent is known to cover the labeled use of bethanechol for urinary retention or neurogenic bladder at present. Any new method-of-use claim would need to distinguish itself from the longstanding clinical use of bethanechol and would face substantial prior-art scrutiny.

Manufacturing and process protection

Bethanechol manufacturing may involve confidential process know-how, supplier qualification, impurity controls, and quality-system capabilities. Those factors can affect market participation, but they are not equivalent to an enforceable patent barrier. The active ingredient is commercially mature, and alternative manufacturing routes are available to qualified pharmaceutical suppliers.

What is the Orange Book status of Urecholine?

The FDA Orange Book is the relevant source for listed prescription drug products, therapeutic-equivalence evaluations, patents, and exclusivity information.[2] Urecholine should not be treated as an actively protected branded product merely because historical Urecholine records may remain visible in regulatory databases.

The key regulatory points are:

1. Historical Urecholine listings may appear as discontinued products or reference-product records.
2. A discontinued brand listing does not create current market exclusivity.
3. Generic bethanechol products may be approved through abbreviated new drug applications.
4. Patent certifications associated with generic applications are not evidence that the underlying molecule remains protected.
5. The Orange Book does not provide a standalone revenue history for Urecholine.

FDA policy distinguishes between a drug being discontinued for commercial reasons and being withdrawn for safety or efficacy reasons. That distinction matters when assessing whether an abbreviated generic approval can reference a historical product.[3]

How many patents cover bethanechol chloride?

The commercially relevant number is effectively zero for active U.S. protection of the basic product. Historical patent documents may exist, and unrelated patents may mention bethanechol in broader chemical or therapeutic claims, but such references do not establish an enforceable patent estate for Urecholine.

Patent category	Current commercial relevance
Active ingredient patent	None identified
Core tablet formulation patent	None identified
Labeled-use patent	None identified
Device or delivery-system patent	Not applicable to standard Urecholine tablets
Manufacturing patent blocking generic entry	None identified
Patent-based exclusivity period	None

This is materially different from branded drugs with active patents covering crystalline forms, extended-release systems, injectors, combination products, or dosing methods.

What is the FDA regulatory status of Urecholine?

Bethanechol is an FDA-approved prescription drug ingredient, but the original Urecholine brand is no longer the center of the market. The FDA-approved labeling supports use in selected forms of urinary retention and bladder atony.[1]

The product does not have a biologics license application, and no biosimilar pathway applies. Biosimilar risk is therefore zero in the technical regulatory sense. The relevant competitive risk is generic substitution.

The FDA regulatory status creates several commercial constraints:

• Bethanechol has a narrow therapeutic role.
• The label limits use to nonobstructive conditions.
• Safety concerns reduce use in patients with asthma, peptic ulcer disease, bradycardia, hypotension, or gastrointestinal obstruction.
• Clinical practice often favors catheterization, intermittent catheterization, alpha-blockers, or treatment of the underlying cause, depending on the patient.
• The drug is not a high-growth specialty product.

Which companies compete with Urecholine?

Competition comes from generic bethanechol suppliers and alternative treatments, not from competing branded versions of Urecholine.

Generic bethanechol manufacturers

Generic bethanechol has historically been marketed by multiple U.S. pharmaceutical companies, including contract and private-label suppliers. Manufacturer participation can change as companies discontinue low-volume products, transfer ANDAs, or shift production to third-party facilities. The commercial market therefore may have fewer active suppliers than the number of FDA-approved applications suggests.

Therapeutic alternatives

The main alternatives depend on the cause of urinary retention:

Alternative	Role relative to bethanechol
Intermittent catheterization	Direct management of retention; often preferred in neurogenic bladder
Indwelling catheterization	Used when immediate or continuous drainage is required
Alpha-1 blockers	Used in selected outlet-obstruction settings
Surgical treatment	Used for anatomical obstruction
Sacral neuromodulation	Used in selected refractory bladder disorders
Intravesical or other bladder therapies	Used according to underlying diagnosis

Bethanechol is therefore exposed to both generic price competition and therapeutic substitution. Its market is not protected by a specialized delivery system or proprietary diagnostic pathway.

What is the financial trajectory for Urecholine?

Urecholine’s financial trajectory is consistent with a late-stage generic product:

1. Brand revenue declined after generic entry.
2. Brand commercialization became economically unattractive as reimbursement shifted toward generic alternatives.
3. Generic sales persisted in a small, fragmented market.
4. Unit pricing remained constrained by substitution and payer negotiation.
5. Revenue is likely stable to declining in nominal terms, with periodic price volatility caused by shortages, supplier exits, or channel changes.

No public company reports Urecholine revenue as a separate line item. Historical Merck financial statements aggregate products into broad pharmaceutical segments and do not provide a standalone Urecholine revenue series.[4] Generic manufacturers generally report broader portfolios rather than product-level revenue for low-volume legacy drugs.

Revenue exposure

The commercial exposure is limited for large pharmaceutical companies but can be meaningful for a small generic supplier if only one or two manufacturers remain active. Revenue sensitivity is driven by:

• Number of active suppliers
• Wholesale acquisition price
• Pharmacy benefit reimbursement
• Hospital and institutional purchasing
• Product shortages
• Manufacturing costs
• Packaging and distribution expenses
• Formulation strength mix

The 5 mg, 10 mg, 25 mg, and 50 mg strengths do not necessarily contribute equally to sales. Demand is likely concentrated in the strengths preferred by local prescribing practices and institutional formularies.

Pricing dynamics

Bethanechol pricing is generally low relative to branded prescription drugs, but low volume can produce uneven retail pricing. A product may be inexpensive at the manufacturer level while generating high cash prices at pharmacies because of dispensing economics, limited stocking, or weak payer coverage.

Generic price erosion is constrained when:

• Few suppliers remain;
• Production batches are small;
• Active pharmaceutical ingredient costs rise;
• Contract manufacturers exit;
• A shortage reduces competitive pressure.

A mature generic can therefore show short-term price increases without gaining durable strategic value.

What generic entry risks exist for Urecholine?

Generic entry is no longer a future risk. It is the established market condition. The commercial risk is generic consolidation, supply interruption, or further price compression.

Risk	Assessment
New generic entrant	Low strategic significance; market is already generic
Brand-to-generic substitution	High and longstanding
Patent litigation	Minimal current risk
Paragraph IV challenge	Historically relevant only during initial generic entry; no current branded barrier identified
Authorized generic competition	Possible historically, but no current strategic importance established
Biosimilar competition	Not applicable
Generic price erosion	High over long periods
Supply disruption	Potentially material because the market is low volume
Therapeutic substitution	Moderate to high
Brand relaunch opportunity	Low

Paragraph IV challenges

Paragraph IV certifications apply when a generic applicant asserts that a listed patent is invalid, unenforceable, or not infringed. Because bethanechol’s core patent protection expired long ago and no meaningful active patent estate is identified, current Paragraph IV litigation is not a central market issue.[5]

Any historical Paragraph IV dispute would have related to the timing of generic approval rather than to a durable patent position. A current investor or licensing analysis should focus on ANDA status, active suppliers, FDA discontinuation records, and manufacturing economics rather than on patent litigation.

What patent litigation affects Urecholine?

No significant current U.S. patent litigation affecting Urecholine or bethanechol chloride is identified. The lack of litigation is consistent with the product’s age, generic status, and limited revenue opportunity.

Potential disputes would more likely involve:

• ANDA ownership or transfer;
• Product quality;
• Manufacturing contracts;
• Supply obligations;
• Trademark use;
• State substitution rules;
• Pricing or reimbursement practices.

Those matters would not create the type of high-value patent litigation associated with protected oncology, immunology, diabetes, or rare-disease products.

Are there licensing deals involving Urecholine?

No major current licensing transaction involving Urecholine is publicly established. Historical commercialization may have involved manufacturing, distribution, or product-rights arrangements, but Urecholine does not appear to have a visible modern licensing platform.

A potential transaction involving bethanechol would likely be structured around:

• Transfer of an ANDA;
• Acquisition of an established generic portfolio;
• Contract manufacturing;
• Regional distribution rights;
• Shortage-driven supply arrangements.

The low price and limited patient population reduce the likelihood of a large upfront licensing payment.

How does Urecholine compare with newer urology drugs?

Urecholine has a lower price and simpler regulatory profile than newer branded urology products, but it lacks commercial differentiation.

Factor	Urecholine / bethanechol	Newer branded urology drugs
Patent protection	None material	Often active
Market price	Low generic pricing	Frequently high
Clinical positioning	Narrow, older indication	Often broader or more targeted
Promotional support	Minimal	Active for commercial brands
Reimbursement	Generic formulary treatment	Prior authorization may apply
Revenue visibility	Low	Usually reported or modeled
Lifecycle opportunity	Limited	Potential label expansion
Litigation risk	Low	Often material

Bethanechol’s value is primarily functional. It is an available low-cost option for selected patients, but it has little capacity to generate expanding pharmaceutical revenue.

What is the geographic coverage of Urecholine?

The strongest commercial relevance is in the United States and other markets with established generic prescription-drug channels. Availability varies by country because bethanechol may be marketed under different names, supplied by local manufacturers, or absent from national formularies.

Geographic factors include:

• National registration status;
• Local generic substitution rules;
• Reimbursement coverage;
• Availability of oral tablet strengths;
• Hospital procurement practices;
• Local manufacturing and import requirements.

A U.S. patent clearance analysis does not establish freedom to operate in Europe, Canada, Japan, or emerging markets. Still, because the active ingredient is old and broadly established, geographic risk is more likely to arise from registration, quality, and supply requirements than from surviving composition patents.

How strong is the Urecholine patent estate?

The patent estate is weak to nonexistent for current commercial purposes. Urecholine has no identified active composition patent, formulation patent, method-of-use patent, or device patent capable of blocking generic competition.

Its principal commercial barriers are operational:

• FDA compliance;
• Product quality;
• Reliable API supply;
• Minimum efficient batch size;
• Distribution access;
• Pharmacy stocking;
• Reimbursement economics.

Those barriers can limit the number of suppliers, but they do not support premium pricing comparable to a patented product.

Key Takeaways

• Urecholine is the historical brand for bethanechol chloride, an oral cholinergic drug used mainly for nonobstructive urinary retention and neurogenic bladder.
• The brand has no meaningful current exclusivity.
• The active ingredient is long off patent, and no material active U.S. patent estate is identified.
• Generic entry is established rather than prospective.
• Current Paragraph IV litigation and patent risk appear minimal.
• Biosimilar competition does not apply because bethanechol is a small molecule.
• No reliable public source reports standalone Urecholine revenue.
• The financial trajectory is mature, low-growth, and likely declining or volatile at the product level.
• Commercial value depends on supplier continuity, generic pricing, and procurement access.
• The principal market risks are generic price erosion, manufacturer exits, shortages, and therapeutic substitution.

FAQs About Urecholine Market and Patent Status

Is Urecholine still available as a brand-name drug?

Urecholine is generally treated as a historical brand, while bethanechol chloride is available through generic manufacturers. Availability of specific strengths and suppliers can change over time.

Does bethanechol have FDA exclusivity?

No meaningful current exclusivity is identified for bethanechol. Its commercial market is generic and lacks the exclusivity profile of a recently approved innovator drug.

Can a company launch a generic version of Urecholine without patent litigation?

Because no material active patent barrier is identified, a company’s main requirements are FDA approval, manufacturing compliance, product sourcing, and commercially viable distribution.

Is bethanechol included in Medicare prescription coverage?

Coverage depends on the specific Medicare Part D plan, formulary, pharmacy network, and product availability. Generic coverage may vary by strength and supplier.

Is Urecholine a high-value licensing or acquisition target?

Generally no. Its value is more likely to arise from portfolio fit, supply continuity, or an ANDA transaction than from patent exclusivity, brand equity, or growth potential.

References

1. U.S. Food and Drug Administration. (n.d.). Bethanechol chloride prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (n.d.). Discontinued drugs. https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files

4. Merck & Co., Inc. (n.d.). Annual reports and filings. https://www.merck.com/investor-relations/financial-information/

5. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-content-and-format-questions-and-answers